Publication | Closed Access

977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer

MedicineImmunologyErlotinib HclImmune Checkpoint InhibitorTumour Blood SupplyPhase I/ii TrialCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyCancer Growth